Subject(s)
Adalimumab/therapeutic use , Etanercept/therapeutic use , Stevens-Johnson Syndrome/drug therapy , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Anti-Bacterial Agents/adverse effects , Ciprofloxacin/adverse effects , Dermatologic Agents/therapeutic use , Female , Humans , Middle Aged , Psoriasis/drug therapy , Stevens-Johnson Syndrome/etiology , Stevens-Johnson Syndrome/prevention & controlABSTRACT
The evaluation of iron status in dialysis patients provides information essential to the planning of adequate recombinant human erythropoietin treatment. The cellular iron status of the patients can be determined from the recently available measurement of reticulocyte hemoglobin equivalent (RET-He). RET-He is measured on the basis of automated fluorescent flow cytometry which in the reticulocyte channel, using a polymethine dye, also measures the mean value of the forward light scatter intensity of mature red blood cells and reticulocytes. These values equate with reticulocyte hemoglobin content. In this study, to clarify the accuracy of RET-He in diagnosing iron deficiency in dialysis patients, we initially compared RET-He with such iron parameters as serum ferritin levels, transferrin saturation and content of reticulocyte hemoglobin (CHr) which has been established as indicators of functional iron deficiency. Secondly, we investigated the changes in RET-He during iron supplementation for iron-deficient patients to determine whether this marker is a prospective and reliable indicator of iron sufficiency. The participants in this study were 217 haemodialysis patients. Iron deficiency was defined as havsing a transferrin saturation (TSAT) < 20% or serum ferritin < 100 ng/ml. Conventional parameters of red blood cells and RET-He were measured by on a XE-2100 automated blood cell counter (Sysmex). CHr was measured on an ADVIA120 autoanalyser (Siemens). RET-He mean value was 32.4 pg and good correlation (r = 0.858) between RET-He and CHr is obtained in dialysis patients. Receiver operating characteristic curve analysis revealed, values of the area was 0.776 and at a cutoff value of 33.0 pg, a sensitivity of 74.3% and a specificity of 64.9%, were achieved. Iron supplements given to the patients with low TSAT or ferritin, RET-He responded within 2 weeks, and this seemed to be a potential advantage of using RET-He in the estimation of iron status. RET-He is a new parameter, equivalent value to CHr, and is easily measurable on the widely spread and popular blood cell counter and is a sensitive and specific marker of iron status in dialysis patients.
Subject(s)
Anemia, Iron-Deficiency/diagnosis , Hemoglobins , Iron Deficiencies , Iron/blood , Renal Dialysis , Reticulocytes/chemistry , Biomarkers/chemistry , Humans , ROC Curve , Reticulocyte CountABSTRACT
AIM: To estimate the likelihood of transfer of kanamycin-resistance gene (nptII) from commercially available genetically modified (GM) plants. METHODS AND RESULTS: Acinetobacter sp. BD413 carrying a plasmid containing an inactivated nptII gene was treated with DNA derived from GM potato and GM papaya. Kanamycin-resistant transformants were obtained at a frequency of 10-30 microg(-1) DNA. Calculation of the results suggested that 6-9 x 10(4) molecules of genomic DNA from GM plants were needed to obtain one transformant. However, such transformation events were not detectable in the absence of the plasmid in the host strain. CONCLUSIONS: Acinetobacter sp. BD413 was transformed with DNA derived from GM potato and GM papaya, in the presence of an inactivated nptII gene on a plasmid. However, the frequency of such events in the natural environment on wild-type strains, while evidently low, remains unknown. SIGNIFICANCE AND IMPACT OF THE STUDY: Our results may help to evaluate potential risks associated with the use of antibiotic-resistance determinants as genetic markers in GM plants. Complete risk assessment must consider factors other than transformation frequency alone, including the natural background of antibiotic resistance present in bacterial populations, and the spectrum and clinical use of the antimicrobial agents in question.
Subject(s)
Acinetobacter/genetics , Carica/genetics , Solanum tuberosum/genetics , Transformation, Bacterial , DNA, Plant/genetics , Kanamycin Resistance/genetics , Plants, Genetically ModifiedABSTRACT
OBJECTIVE: To establish a new method for preoperative bowel preparation that facilitates nursing care and minimizes the patient's discomfort during the clinical pathway of laparoscopic surgery. METHOD: A randomized controlled trial was conducted for the following two preparation methods. Twenty cases were assessed with Method 1 and 18 cases with Method 2. Method 1 (the conventional procedure): oral magnesium citrate is given in the afternoon of the day before surgery, followed by a glycerin enema in the night of the day before surgery and in the morning of the day of surgery. Method 2 (a new procedure): oral magnesium citrate is given in the afternoon of the day before surgery, followed by oral picosulfate in the night before the day of surgery and a bisacodyl suppository in the morning of the day of surgery. To evaluate the two methods we sent questionnaires to the surgeons (blinded to the method used), nurses, and patients. RESULTS: No statistical difference existed between the two methods in their effectiveness as a preoperative treatment. Facilitation of nursing care was significantly better in Method 2, and patients had considerably reduced discomfort with Method 2. DISCUSSION: Patients who received oral picosulfate and a bisacodyl suppository experienced much less discomfort and nursing care was easier when compared with the conventional method of administering a glycerin enema. Since an enema is disliked by young women and an effect comes out with discomfort very shortly after the administration, the degree of discomfort of patients would have become high. Picosulfate is an oral medicine and thereby the effect comes out mildly. That would be the reason why the degree of discomfort of patients was low. In the nursing care, an enema requires time for preparation and administration, while picosulfate is easy to administer, making the nursing care easier. Therefore, Method 2 was chosen as a preoperative bowel treatment for the clinical pathway. Thus, we could establish a new evidence-based method useful for the preoperative bowel preparation in the clinical pathway of laparoscopic surgery.
Subject(s)
Enema/methods , Gynecologic Surgical Procedures , Laparoscopy , Preoperative Care/methods , Therapeutic Irrigation/methods , Adult , Female , Humans , Middle Aged , Surveys and QuestionnairesABSTRACT
Troglitazone (TGZ), an antidiabetic drug that improves insulin-resistance in the peripheral tissues, was tested for neurotrophic activity in motoneurones and other neurones in culture. In rat motoneurones, TGZ had a remarkable effect on survival, which was comparable or superior to that of brain-derived neurotrophic factor, a known potent neurotrophic factor for rat motoneurones. However, TGZ did not promote the survival of sensory, sympathetic, septal or hippocampal neurones. The effect of TGZ on motoneurones was additive to that of insulin-like growth factor-I and both activities were inhibited by phosphatidylinositol 3-kinase (PI3-kinase) inhibitors, wortmannin and LY294002, suggesting the involvement of the activation of PI3-kinase in the activity of TGZ. Pioglitazone, another antidiabetic drug structurally similar to TGZ, did not show any activity, indicating that the agonistic activity of TGZ for peroxisome proliferator-activated receptor-gamma is not involved in the survival activity. Chromanol, an antioxidant moiety of TGZ, showed little or no survival activity. These results indicate specific neurotrophic activity of TGZ for motoneurones through the activation of PI3-kinase and support the applicability of TGZ for the treatment of motor neurone diseases such as amyotrophic lateral sclerosis.
Subject(s)
Antioxidants/pharmacology , Chromans/pharmacology , Motor Neurons/drug effects , Thiazoles/pharmacology , Thiazolidinediones , Animals , Brain-Derived Neurotrophic Factor/pharmacology , Cell Survival/drug effects , Cells, Cultured , Drug Evaluation, Preclinical , Enzyme Activation/drug effects , Enzyme Inhibitors/pharmacology , Hippocampus/cytology , Hippocampus/drug effects , Insulin-Like Growth Factor I/pharmacology , Motor Neurons/cytology , Neurons, Afferent/cytology , Neurons, Afferent/drug effects , Phosphoinositide-3 Kinase Inhibitors , Pioglitazone , Rats , Receptors, Cytoplasmic and Nuclear/agonists , Septum of Brain/cytology , Septum of Brain/drug effects , Spinal Cord/cytology , Spinal Cord/drug effects , Spinal Cord/embryology , Sympathetic Nervous System/cytology , Sympathetic Nervous System/drug effects , Transcription Factors/agonists , TroglitazoneABSTRACT
We purified a compound with strong inhibitory effect on H+, K(+)-ATPase from Paeoniae radix, which has been used in Japan for the treatment of gastritis and peptic ulcers. The compound was identified as 1,2,3,4,6,-penta-o-galloyl-beta-D-glucose by proton nuclear magnetic resonance, carbon-13 nuclear magnetic resonance, and fast atomic bombardment mass spectrometry. The IC50 of the compound for H+, K(+)-ATPase was 166 nmol/l. Kinetic analyses indicated that the inhibition of the enzyme by pentagalloylglucose was noncompetitive with respect to K+. Pentagalloylglucose had relatively weak inhibitory effects for Mg(+)-ATPase (IC50: > 10 mumol/l) and Na+, K(+)-ATPase (IC50: 2.7 mumol/l). Pentagalloylglucose also inhibited the accumulation of [14C]aminopyrine in parietal cells that had been isolated from guinea pig stomach and stimulated by 10 mumol/l histamine (IC50: 7.8 mumol/l) and 1 mmol/l dbc-AMP (IC50: 10 mumol/l). These results suggest that pentagalloylglucose is a potent inhibitor of H+, K(+)-ATPase and may be responsible for inhibition of acid secretion by Paeoniae radix.
Subject(s)
Drugs, Chinese Herbal/pharmacology , Hydrolyzable Tannins , Parietal Cells, Gastric/enzymology , Proton Pump Inhibitors , Tannins/pharmacology , Aminopyrine/antagonists & inhibitors , Animals , Ca(2+) Mg(2+)-ATPase/antagonists & inhibitors , Cells, Cultured , Enzyme Inhibitors/pharmacology , Gastric Acid/metabolism , Guinea Pigs , Japan , Kinetics , Male , Parietal Cells, Gastric/drug effects , Parietal Cells, Gastric/metabolism , Tannins/isolation & purificationSubject(s)
Neuropeptides/chemistry , Neuropeptides/pharmacokinetics , Panax/chemistry , Plant Extracts/pharmacokinetics , Plants, Medicinal , 1-Methyl-3-isobutylxanthine/pharmacology , Animals , Cell Line , Cyclic AMP/metabolism , Humans , Male , Neuropeptides/isolation & purification , Pituitary Adenylate Cyclase-Activating Polypeptide , Plant Extracts/chemistry , Plant Roots/chemistry , Radioimmunoassay , Rats , Rats, WistarABSTRACT
We recently demonstrated that centrally administered melatonin at low doses inhibits the induction of gastric lesions by water-immersion restraint stress. To investigate the mechanism of the potent anti-ulcer action of melatonin, the central nervous system (CNS) effects of melatonin on gastric acid and pepsin secretion were studied in conscious pylorus-ligated rats. Intracisternal (i.c.) melatonin (1-100 ng) dose-dependently decreased acid and pepsin output, while a higher i.p. dose (1 microg) had no inhibitory effect. The i.c. melatonin did not change serum gastrin concentrations. Serum melatonin concentrations at 1 and 4 h after i.c. administration of 10-100 ng melatonin did not differ from those in rats receiving i.c. vehicle. The present results suggest that melatonin administered centrally modulates the secretion of gastric acid and pepsin which may explain, at least in part, the protective, anti-stress role of melatonin in the gastric mucosa observed in our previous study.